Bionano Genomics, Inc. Announces Pricing of $10 Million Public Offering
Bionano Genomics (NASDAQ: BNGO) has announced the pricing of a $10 million public offering consisting of 5,000,000 shares of common stock (or equivalents) and accompanying warrants at $2.00 per share. The offering includes Series E warrants with a 5-year term and Series F warrants with an 18-month term, both with a $2.00 exercise price.
If all warrants are fully exercised, the company could receive additional gross proceeds of approximately $20 million. H.C. Wainwright & Co. is serving as the exclusive placement agent. The offering is expected to close around September 17, 2025, with proceeds intended for working capital and general corporate purposes.
Bionano Genomics (NASDAQ: BNGO) ha annunciato la fissazione del prezzo di un'offerta pubblica da 10 milioni di dollari composta da 5.000.000 azioni ordinarie (o equivalenti) e warrant accompagnatori al prezzo di 2,00 dollari per azione. L'offerta include warrant di Serie E con una durata di 5 anni e warrant di Serie F con una durata di 18 mesi, entrambi con un prezzo di esercizio di 2,00 dollari.
Se tutti i warrant saranno esercitati integralmente, la società potrebbe ricevere fondi lordi aggiuntivi di circa 20 milioni di dollari. H.C. Wainwright & Co. è l'agente di collocamento esclusivo. L'offerta dovrebbe chiudersi intorno al 17 settembre 2025, con i proventi destinati a capitale circolante e a scopi generali aziendali.
Bionano Genomics (NASDAQ: BNGO) ha anunciado el precio de una oferta pública de 10 millones de dólares que consiste en 5.000.000 de acciones comunes (o equivalentes) y warrants acompañantes a 2,00 dólares por acción. La oferta incluye warrants de la Serie E con un plazo de 5 años y warrants de la Serie F con un plazo de 18 meses, ambos con un precio de ejercicio de 2,00 dólares.
Si todos los warrants se ejercen por completo, la compañía podría recibir ingresos brutos adicionales de aproximadamente 20 millones de dólares. H.C. Wainwright & Co. actúa como agente de colocación exclusivo. Se espera que la oferta cierre alrededor del 17 de septiembre de 2025, y los ingresos se destinarán a capital de trabajo y a fines corporativos generales.
Bionano Genomics (NASDAQ: BNGO)가 주당 2.00달러의 가격으로 5,000,000주 보통주(또는 동등한 주식) 및 동반 워런트를 포함하는 1천만 달러 규모의 공모를 가격 책정했다고 발표했습니다. 본 공모에는 5년 만기의 E 시리즈 워런트와 18개월 만기의 F 시리즈 워런트가 포함되며, 두 워런트의 행사가격은 2.00달러입니다.
모든 워런트를 완전히 행사할 경우 회사가 추가로 약 2000만 달러의 총수익을 받을 수 있습니다. H.C. Wainwright & Co.가 독점 배정 대리인으로 활동합니다. 공모는 2025년 9월 17일경 체결될 예정이며, 수익은 운전자본 및 일반 기업 용도로 사용될 예정입니다.
Bionano Genomics (NASDAQ : BNGO) a annoncé le prix d'une offre publique de 10 millions de dollars se décomposant en 5 000 000 d'actions ordinaires (ou équivalents) et des warrants accompagnants à 2,00 dollars par action. L'offre comprend des warrants de série E d'une durée de 5 ans et des warrants de série F d'une durée de 18 mois, les deux à un prix d'exercice de 2,00 dollars.
Si tous les warrants sont exercés pleinement, la société pourrait percevoir des produits bruts supplémentaires d'environ 20 millions de dollars. H.C. Wainwright & Co. agit comme agent de placement exclusif. La clôture de l'offre est attendue autour du 17 septembre 2025, les produits étant destinés à fonds de roulement et à des besoins généraux de l'entreprise.
Bionano Genomics (NASDAQ: BNGO) hat den Preis einer öffentlichen Emission über 10 Millionen USD bekanntgegeben, die 5.000.000 Stammaktien (oder gleichwertige Wertpapiere) und begleitende Warrants zum Preis von 2,00 USD pro Aktie umfasst. Die Emission enthält Serie-E-Warrants mit einer Laufzeit von 5 Jahren und Serie-F-Warrants mit einer Laufzeit von 18 Monaten, beide mit einem Ausübungspreis von 2,00 USD.
Sollten alle Warrants vollständig ausgeübt werden, könnte das Unternehmen zusätzliche Bruttoerlöse von ca. 20 Millionen USD erzielen. H.C. Wainwright & Co. fungiert als exklusiver Platzierungsagent. Der Abschluss der Emission wird voraussichtlich um den 17. September 2025 erfolgen, die Erlöse sollen für Betriebskapital und allgemeine Unternehmenszwecke verwendet werden.
Bionano Genomics (ش.م.ب: BNGO) أعلنت عن تسعير عرض عام بقيمة عشرة ملايين دولار يتكون من 5,000,000 سهم عادي (أو ما يعادله) ومشتقات warrants المصاحبة بسعر تنفيذ 2.00 دولار للسهم. يتضمن العرض warrants من السلسلة E لمدة 5 سنوات ومشتقات warrants من السلسلة F لمدة 18 شهراً، وكلاهما بسعر تنفيذ 2.00 دولار.
إذا تم ممارسة جميع warrants بالكامل، قد تحصل الشركة على عوائد إجمالية إضافية تبلغ حوالي 20 مليون دولار. تعمل H.C. Wainwright & Co. كوكيل طرح حصري. من المتوقع أن يغلق العرض نحو 17 سبتمبر 2025، وستخصص العوائد للمتداولات الرأسمالية والغايات العامة للشركة.
Bionano Genomics(纳斯达克代码:BNGO) 已宣布定价一项1000万美元的公开发行,包含5,000,000股普通股(或同等证券)及随附认股权证,行权价为每股2.00美元。发行包括5年期的E系列认股权证和18个月期的F系列认股权证,二者行权价均为2.00美元。
若所有认股权证全部行使,公司还可能获得约2000万美元的额外毛收益。H.C. Wainwright & Co.为独家配售代理。预计发行将在2025年9月17日左右完成,募集资金将用于运营资本和公司一般用途。
- Potential for additional $20 million in gross proceeds if warrants are fully exercised
- Strengthens working capital position with $10 million gross proceeds
- Dilutive effect on existing shareholders through 5 million new shares
- Additional potential dilution from 10 million warrant shares if exercised
- Offering price represents a likely discount to market price
Insights
Bionano's $10M offering with potential $20M from warrants will dilute shareholder value while providing necessary operating capital.
Bionano Genomics has priced a
The offering price of
For existing shareholders, this offering represents significant dilution, as 5 million new shares are being issued, with potential for an additional 10 million shares if all warrants are exercised. The company's statement that proceeds will be used for "working capital and general corporate purposes" indicates these funds are likely needed for ongoing operations rather than specific growth initiatives.
H.C. Wainwright's role as exclusive placement agent suggests the company is working with specialized financial firms to secure this capital. The offering is expected to close around September 17, 2025, providing Bionano with near-term liquidity to support its operations. However, the company explicitly notes there's "no assurance" the warrants will be exercised, highlighting uncertainty around the full
SAN DIEGO, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) (“Bionano” or the “Company”) today announced the pricing of a public offering of an aggregate of 5,000,000 shares of the Company’s common stock (or common stock equivalents in lieu thereof), Series E warrants to purchase up to 5,000,000 shares of the Company’s common stock and short-term Series F warrants to purchase up to 5,000,000 shares of the Company’s common stock (all the warrants, collectively, the “Series Warrants”), at a combined public offering price of
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
The aggregate gross proceeds to the Company from the offering are expected to be approximately
The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-290187), which was declared effective by the Securities and Exchange Commission (the “SEC”) on September 16, 2025. The offering is being made only by means of a prospectus forming part of the effective registration statement relating to the offering. A preliminary prospectus relating to the offering has been filed with the SEC and is available on the SEC’s website at http://www.sec.gov and a final prospectus relating to the offering will be filed with the SEC. Electronic copies of the final prospectus, when available, may be obtained on the SEC’s website at http://www.sec.gov and may also be obtained, when available, by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Bionano
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services.
For more information, visit www.bionano.com or www.bionanolaboratories.com.
Bionano’s products are for research use only and not for use in diagnostic procedures.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the consummation of the offering and the satisfaction of customary closing conditions related to the offering, the use of proceeds therefrom, and the exercise of the Series Warrants in cash prior to their expiration. Each of these forward-looking statements involves risks and uncertainties. Accordingly, investors and prospective investors are cautioned not to place undue reliance on these forward-looking statements as they involve inherent risk and uncertainty (both general and specific) and should note that they are provided as a general guide only and should not be relied on as an indication or guarantee of future performance. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the failure of the Category I CPT code to drive use and adoption of the OGM-Dx Postnatal Whole Genome SV, OGM-Dx Prenatal Whole Genome SV and other OGM-based tests; the failure of the OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV tests to obtain coverage and reimbursement; the failure of the Category I CPT code to prove to be important for clinical OGM testing; the failure of OGM to outperform legacy cytogenomic methods; the timing and amount of revenue we are able to recognize in a given fiscal period; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts and our ability to continue as a “going concern,” which requires us to manage costs and obtain significant additional financing to fund our strategic plans and commercialization efforts; the risk that if we fail to obtain additional financing we may seek relief under applicable insolvency laws; the impact of adverse geopolitical and macroeconomic events, such as the ongoing conflicts between Ukraine and Russia and Israel and Gaza and uncertain market conditions, including inflation, tariffs, and supply chain disruptions, on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; changes in our strategic and commercial plans; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; study results that differ or contradict the results mentioned in this press release; the risk that we are not able to complete a strategic transaction that would increase stakeholder value; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2024, our Quarterly Reports on Form 10-Q and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise, except as may be required by law.
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionano.com
Investor Relations:
Kelly Gura
Gilmartin Group
+1 (212) 229-6163
IR@bionano.com
